Literature DB >> 16835400

The PPARgamma agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant rats.

Anne Zanchi1, Christine Perregaux, Marc Maillard, Daniel Cefai, Juerg Nussberger, Michel Burnier.   

Abstract

Glitazones are efficient insulin sensitizers that blunt the effects of angiotensin II (ANG II) in the rat. Sodium chloride is another important modulator of the systemic and renal effects of ANG II. Whether glitazones interfere with the interaction between sodium and the response to ANG II is not known. Therefore, we investigated the effects of pioglitazone on the relationship between sodium and the systemic and renal effects of ANG II in rats. Pioglitazone, or vehicle, was administered for 4 wk to 8-wk-old obese Zucker rats. Animals were fed a normal-sodium (NS) or a high-sodium (HS) diet. Intravenous glucose tolerance tests, systemic and renal hemodynamic responses to ANG II, and the renal ANG II binding and expression of ANG II type 1 (AT(1)) receptors were measured. The results of our study were that food intake and body weight increased, whereas blood pressure, heart rate, filtration fraction, and insulin levels decreased significantly with pioglitazone in obese rats on both diets. Pioglitazone blunted the systemic response to ANG II and abolished the increased responsiveness to ANG II induced by a HS diet. Pioglitazone modified the renal hemodynamic response to changes in salt intake while maintaining a lower filtration fraction with ANG II perfusion. These effects were associated with a decrease in the number and expression of the AT(1) receptor in the kidney. In conclusion, these data demonstrate that the peroxisome proliferator-activated receptor-gamma agonist pioglitazone modifies the physiological relationship between sodium chloride and the response to ANG II in insulin-resistant rats.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16835400     DOI: 10.1152/ajpendo.00171.2006

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  3 in total

1.  Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals.

Authors:  A Zanchi; M Maillard; F R Jornayvaz; M Vinciguerra; P Deleaval; J Nussberger; M Burnier; A Pechere-Bertschi
Journal:  Diabetologia       Date:  2010-04-23       Impact factor: 10.122

2.  Pioglitazone in diabetic kidney disease: forgotten but not gone.

Authors:  Georgios S Papaetis
Journal:  Arch Med Sci Atheroscler Dis       Date:  2022-08-08

3.  Renoprotective and haemodynamic effects of adiponectin and peroxisome proliferator-activated receptor agonist, pioglitazone, in renal vasculature of diabetic Spontaneously hypertensive rats.

Authors:  Sheryar Afzal; Munavvar Abdul Sattar; Edward James Johns; Olorunfemi A Eseyin
Journal:  PLoS One       Date:  2020-11-10       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.